In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 

1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/

2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/

3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/

4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.00843

5. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/

https://pubmed.ncbi.nlm.nih.gov/28976863/

6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL: 

https://pubmed.ncbi.nlm.nih.gov/39447094/

7. Epcoritamab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/38889737/

8. Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: https://ashpublications.org/blood/article/144/Supplement%202/LBA-1/534319

9. Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance in Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.19.01073

In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. 
https://pubmed.ncbi.nlm.nih.gov/39841461/
https://pubmed.ncbi.nlm.nih.gov/40459097/

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: 

• ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022
• Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6
• DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79
• AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826
• Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutated
• KOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstract
• SAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-of
• KOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595
• MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9

In this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and slides: 

https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025#event-materials

Here is the youtube link for FDA proceedings: 

https://www.youtube.com/watch?v=5ecyDbK9ezc

In this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies we discussed:

• Midostaurin https://www.nejm.org/doi/10.1056/NEJMoa1513098?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
• Avapritinib
• EXLPORER study: https://www.nature.com/articles/s41591-021-01538-9
• PATHFINDER study: https://www.nature.com/articles/s41591-021-01539-8
• Bezuclastinib: APEX trial: https://ashpublications.org/blood/article/144/Supplement%201/659/530240/Apex-Part-1-Updated-Assessment-of-Bezuclastinib
• HSCT for Advanced SM: https://ascopubs.org/doi/10.1200/JCO.2014.55.2018

In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: 

1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/

2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/

3. Other CTTLN cases in myeloma:
https://pubmed.ncbi.nlm.nih.gov/38865661/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/

4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: 

Older AML: Ven+HMA vs 7+3

Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html

Abstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.html

Abstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.html

Venetoclax resistance mechanisms

https://pubmed.ncbi.nlm.nih.gov/39478230/

FLAG-GO vs FLAG-IDA 

https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine

 CPX-351: 

Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.html

Abstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.html

Menin Inhibitors 

Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.html

Abstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.html

Abstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.html

Abstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html

FLT3 inhibitors
Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html

MDS

 Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html

ATRA in MDS:  

https://ash.confex.com/ash/2024/webprogram/Paper200433.html 

In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 

1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. 

https://pubmed.ncbi.nlm.nih.gov/38820078/

2. 5-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/26837842/

3. 10-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/33414482/

4. 10-year follow-up of CML-IV RCT (imatinib): 

https://pubmed.ncbi.nlm.nih.gov/25676422/

5. MD Anderson data on low-dose dasatinib (50 mg): 

https://pubmed.ncbi.nlm.nih.gov/36054032/

https://pubmed.ncbi.nlm.nih.gov/31553487/

6. CML: 2025 update on diagnosis, therapy, and monitoring: 

https://pubmed.ncbi.nlm.nih.gov/39093014/

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:

1. AQUILA Trial in High-Risk SMM

• Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
•  Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
•  Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
•  Read the abstract.
•  Read the simultaneous publication at NEJM. 

2. Anito-Cel: New BCMA CAR T Therapy

•  Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
•  Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
•  Read the abstract.

3. CARTITUDE-4 Update

•  Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
•  Read the abstract.

4. ANDROMEDA OS Data in AL Amyloidosis

•  Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
•  Insights into cardiac responses and crossover impact.
•  Read the abstract.

5. OPTIMUM Trial in Ultra-High-Risk NDMM

• Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. 
• Subgroup outcomes highlighting both challenges and exceptional results.
•  Read the abstract

6. GMMG-HD7 Trial PFS Update

•  Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT.
•  Discussion on the role of CD38 in maintenance therapy.
•  Read the abstract
•  Read the simultaneous publication at JCO

7. Exciting New Drugs

•  Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
•  Expert insights into their efficacy and potential to reshape myeloma care.
•  Read the abstract

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 

1. 3 RCTs in Mantle Cell Lymphoma: 

a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.html

b) ENRICH Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.html

c) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html

2. DLBCL: 

a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.html

b) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.html

c) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html

3. Follicular Lymphoma: 

a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.html

b) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract

4. CLL: 

a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html

5. Hodgkin Lymphoma: 

a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html